- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02117141
To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules
November 8, 2022 updated by: Zogenix, Inc.
A Pilot Study in Healthy Volunteers to Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules, in Both Fed and Fasted States
- Assess the rate and extent of absorption of hydrocodone from a 20 mg HC-ER capsule in both fed and fasted states
- Evaluate the safety and tolerability of the test compound administered orally
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Safety parameters assessed included medical history, physical examination, vital signs, 12-lead ECGs, clinical laboratory testing and adverse event assessment.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy Volunteers.
- Aged greater than 18 and less than 45 years.
- Were medically healthy with no clinically significant abnormality on the basis of medical history, physical examination and laboratory evaluations
- Volunteer consented to participate in the study.
- Female volunteers were included if they were surgically sterile, or using an acceptable method of birth control defined as either oral, injectable, implantable, or barrier methods of contraception (ie, diaphragm with spermicidal cream, intrauterine device (IUD) with spermicidal cream or condom with spermicidal cream).
Exclusion Criteria:
- Participants were in a clinical trial within the previous 90 days or participants in a narcotic analgesic study within the previous 12 months.
- Deviation in excess of 10% from the ideal body weight for height according to the Metropolitan Life Insurance Tables (1983 edition).
- History of drug or alcohol abuse at any time in the past
- History of hypersensitivity to the study drug or similar compounds or to acetaminophen.
- Therapeutic use (for any reason) of narcotic analgesics within the previous year.
- Subjects who used tricyclic antidepressants or monoamine oxidase inhibitors at any time in the past.
- Subjects with a history of, or clinical signs suggestive of, chronic obstructive airways disease.
- Receipt of any prescription medication (except birth control) within 2 weeks prior to entry into the study or receipt of non-prescription or over-the-counter medication within one week of study commencement. (Vitamin supplements were acceptable).
- Blood donation within the 90 days previous to study entry.
- Female volunteers with a positive serum pregnancy test, or at risk of becoming pregnant during the study.
- Volunteers with a history of smoking (must not have smoked within the last 6 months).
- Volunteers with any clinical/biochemical impairment of liver function, or receipt of known hepatic enzyme inducing or inhibiting agents within 30 days prior to entry into the study.
- History or presence of significant hepatic, renal, endocrine, cardiac, nervous, gastrointestinal, pulmonary or metabolic disorders.
- Any condition or history that the investigator considered might increase the risk to the volunteer or interfere with the evaluation of data.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HC-ER 20 mg capsule (fasted)
Single oral dose of a HC-ER 20 mg capsule (fasted)
|
Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
Other Names:
|
Experimental: HC-ER 20 mg capsule (fed)
Single oral dose of HC-ER 20mg capsule (fed)
|
Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the rate and extent of absorption of hydrocodone from a 20 mg HC-ER capsule in both fed and fast states
Time Frame: Day 1-2
|
Day 1-2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: A. Johnston Stewart, MB, MRCGP, Zogenix, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2002
Primary Completion (Actual)
June 1, 2002
Study Completion (Actual)
June 1, 2002
Study Registration Dates
First Submitted
April 15, 2014
First Submitted That Met QC Criteria
April 15, 2014
First Posted (Estimate)
April 17, 2014
Study Record Updates
Last Update Posted (Actual)
November 10, 2022
Last Update Submitted That Met QC Criteria
November 8, 2022
Last Verified
April 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ELN-0302002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on HC-ER 20 mg capsule (fasted)
-
Zogenix, Inc.Completed
-
Eisai Inc.CompletedPurpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic PurpuraNetherlands
-
Zogenix, Inc.Completed
-
Vanda PharmaceuticalsCompletedNon-24-Hour-Sleep-Wake Disorder
-
TaiRx, Inc.CompletedAdvanced CancerTaiwan
-
AstraZenecaCompletedZollinger-Ellison Syndrome | Reflux Esophagitis (RE) | Gastric Ulcer (GU) | Duodenal Ulcer (DU) | Anastomotic Ulcer (AU) | Non-erosive Reflux Esophagitis Disease (NERD)Japan
-
Ixchelsis LimitedCompleted
-
Impax Laboratories, LLCCompletedMultiple SclerosisUnited States, Canada, Estonia, Latvia, Ukraine
-
Zogenix, Inc.Completed
-
Zogenix, Inc.Completed